Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Arcturus Therapeutics ARCT in the last three months. The table below summarizes their recent ...

Neda Safarzadeh, Sr. Director, Head of IR, PR & Marketing, Arcturus Therapeutics Holdings Inc., San Diego, CA, USA, Tel: +1-858-900-2682 Arcturus Therapeutics, based ...

Collectively, these elements underscore Arcturus Therapeutics’ capacity for innovation and market penetration, justifying the Buy rating. ARCT’s price has also changed moderately for the past ...

Arcturus is advancing its vaccine and rare disease pipeline with significant developments. The initiation of a BARDA-funded Phase 1 study for bird flu, along with ongoing studies in cystic ...

Fintel reports that on January 28, 2025, BTIG initiated coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a Buy recommendation. As of December 23, 2024, the average one-year price ...